Alaa H A Hegazy, Olga Pérez-Quílez, Israel López-Muñoz, Anna Chamorro, Elena Abad, Alba San José, Júlia Valera, Lluís Valerio, Laura Soldevila, Ester Gorriz, Dolores Herena, Elia Fernández-Pedregal, Josep M Llibre, Gema Fernández-Rivas, Pere Joan Cardona, Xavier Vallès, Sílvia Roure
{"title":"Performance (Sensitivity and Specificity) of a New Point-of-Care Immunochromatography to Screen for Imported Chronic Schistosomiasis Among Long-Term Sub-Saharan Migrants.","authors":"Alaa H A Hegazy, Olga Pérez-Quílez, Israel López-Muñoz, Anna Chamorro, Elena Abad, Alba San José, Júlia Valera, Lluís Valerio, Laura Soldevila, Ester Gorriz, Dolores Herena, Elia Fernández-Pedregal, Josep M Llibre, Gema Fernández-Rivas, Pere Joan Cardona, Xavier Vallès, Sílvia Roure","doi":"10.1093/ofid/ofaf328","DOIUrl":"10.1093/ofid/ofaf328","url":null,"abstract":"<p><strong>Background: </strong>Imported schistosomiasis is underdiagnosed among long-term migrants in non-endemic countries. Reference standard tests are lacking for the diagnosis of chronic schistosomiasis.</p><p><strong>Methods: </strong>This study evaluated the sensitivity and specificity of a new immunochromatography (ICT) test using serum (s) or point-of-care finger-prick (FP) whole blood against standard serological tests in long-term migrants from sub-Saharan Africa.</p><p><strong>Results: </strong>A total of 202 individuals were screened, with a mean age of 42.7 years. Of these, 75.7% were male, and 42.6% were from Senegal. Test positivity rates were 15.8% for ELISA, 24.3% for ICT-p, 46.5% for ICT-b (s), and 28.7% for ICT-b (FP). All tests showed good agreement with a clinical score but with heterogeneous agreement between them. Our results indicates a higher sensitivity for ICT-b (s). Positive responses after treatment suggest good specificity for all tests.</p><p><strong>Conclusions: </strong>ICT-b (s) shows a higher sensitivity than the other standard tests. An ICT-b (FP) strategy could be used as a first-step point-of-care screening tool for probable chronic schistosomiasis.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf328"},"PeriodicalIF":3.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sharon L Walmsley, Princy N Kumar, Chloe Orkin, Melanie Thompson, Kathleen Squires, Zhi Jin Xu, Wayne Greaves, Rebeca M Plank, Yohance Whiteside, Rima Lahoulou
{"title":"Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.","authors":"Sharon L Walmsley, Princy N Kumar, Chloe Orkin, Melanie Thompson, Kathleen Squires, Zhi Jin Xu, Wayne Greaves, Rebeca M Plank, Yohance Whiteside, Rima Lahoulou","doi":"10.1093/ofid/ofaf356","DOIUrl":"10.1093/ofid/ofaf356","url":null,"abstract":"<p><strong>Background: </strong>Females and persons of Black race are often underrepresented in clinical trials. This post hoc analysis of data from three phase 3 studies evaluated the efficacy and safety of doravirine (DOR) by sex and race in adults living with HIV-1.</p><p><strong>Methods: </strong>DRIVE-FORWARD and DRIVE-AHEAD open-label extensions were pooled; participants randomized to first-line DOR-based regimen continued from week (W) 96 to W192 (DOR-continued group) and participants randomized to comparators switched to DOR from W96 to W192 (DOR-switch group). In DRIVE-SHIFT, virologically suppressed adults were randomized to switch to a DOR-based regimen on day 1 (immediate-switch group) or W24 (delayed-switch group) and continued through W144. Results are reported by sex assigned at birth (male vs female) and race (Black vs non-Black).</p><p><strong>Results: </strong>Across trials, female and Black participants each represented <20% of study populations. After continuing or switching to DOR, percentages of participants with HIV-1 RNA <50 copies/mL were comparable between sex and race subgroups. Mean changes in CD4+ T-cell counts and proportions of participants with drug-related adverse events or serious adverse events were generally similar between subgroups. In DRIVE-SHIFT, higher rates of nontreatment-related discontinuations were observed within Black versus non-Black subgroups. Differences in median weight change were generally larger between race subgroups than sex subgroups, although interquartile ranges were wide for all.</p><p><strong>Conclusions: </strong>Participants who continued or switched to DOR generally had comparable efficacy and safety outcomes across sex and race subgroups. However, the sample size was limited. Future studies should ensure greater diversity when investigating factors leading to outcome disparities. <b>ClinicalTrials.gov:</b> NCT02275780, NCT02403674, NCT02397096.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf356"},"PeriodicalIF":3.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aaron Richterman, Caroline O'brien, Fatemeh Ghadimi, Elijah Sumners, Andre Ford, Nafisah Houston, Sebrina Tate, Nancy Aitcheson, Hervette Nkwihoreze, John B Jemmott, Florence Momplaisir
{"title":"Responding to Emerging Epidemics: Insights From Stakeholders on Mpox Vaccine Rollout in Philadelphia.","authors":"Aaron Richterman, Caroline O'brien, Fatemeh Ghadimi, Elijah Sumners, Andre Ford, Nafisah Houston, Sebrina Tate, Nancy Aitcheson, Hervette Nkwihoreze, John B Jemmott, Florence Momplaisir","doi":"10.1093/ofid/ofaf417","DOIUrl":"https://doi.org/10.1093/ofid/ofaf417","url":null,"abstract":"<p><strong>Background: </strong>The 2022 mpox outbreak serves as an important example of a rapidly emerging epidemic that disproportionately affected marginalized populations. Despite the availability of a preventive vaccine, its deployment ultimately fell short of reaching the populations at greatest risk. Therefore, we sought to evaluate the vaccination campaign from the perspectives of key stakeholders.</p><p><strong>Methods: </strong>We conducted semistructured interviews to assess knowledge and perceptions of mpox, as well as barriers and facilitators to vaccine uptake in Philadelphia. We recruited health care clients and community members who were eligible for mpox vaccination and health care workers and community-based organization staff involved in vaccination efforts. We used purposeful selection to ensure inclusion of people with HIV. We used an integrated analysis approach that combined modified grounded theory and implementation science constructs.</p><p><strong>Results: </strong>We interviewed 21 health care clients, 9 community members, 10 health care workers, and 3 community-based organization staff after the primary mpox response in 2022 between February 2023 and October 2024. Participants varied in their knowledge and perceptions of mpox risk, primarily varying based on the perceived importance of sexual identity vs sexual behaviors. They generally believed that at-risk individuals should be vaccinated. Participants reported trusting mpox information from sources they trusted for other health information, such as health departments or knowledgeable members of social networks. Most participants expressed concern about inequitable distribution of the vaccine. Commonly reported facilitators to vaccination included one's own risk perception, technological literacy, co-locating vaccinations with existing clinical and social spaces, and outreach through trusted health-, community-, and social network-based resources. Knowledge, administrative (eg, difficulty signing up), and logistical (eg, limited clinic hours) barriers to vaccine access were thought to exacerbate inequities.</p><p><strong>Conclusions: </strong>While an effective mpox vaccine was a key asset in the response, barriers related to availability, accessibility, awareness, and logistical constraints limited its reach to those at highest risk.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf417"},"PeriodicalIF":3.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soheila Aghlmandi, Kurt Schmidlin, Carola Huber, Pascal Godet, Katharina Kusejko, Marcel Stoeckle, Matthias Cavassini, Huldrych F Günthard, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Cornelia Staehelin, Niklaus D Labhardt, Heiner C Bucher
{"title":"Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data.","authors":"Soheila Aghlmandi, Kurt Schmidlin, Carola Huber, Pascal Godet, Katharina Kusejko, Marcel Stoeckle, Matthias Cavassini, Huldrych F Günthard, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Cornelia Staehelin, Niklaus D Labhardt, Heiner C Bucher","doi":"10.1093/ofid/ofaf410","DOIUrl":"https://doi.org/10.1093/ofid/ofaf410","url":null,"abstract":"<p><strong>Background: </strong>In Switzerland detailed individual patient data are lacking on trends in health care costs, major drivers of costs, and the contribution of breakthrough innovations, such as direct-acting agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection in people with HIV (PWH).</p><p><strong>Methods: </strong>We linked anonymized data of patients undergoing antiretroviral therapy (ART) or naive patients initiating ART between 2012 and 2017 in the Swiss HIV Cohort Study with claims data of health insurers covering 35% of Swiss residents. Trends in mean annual costs for overall care, ART, and hospitalizations were calculated with an adjustment of costs for censoring. Changes in costs over time in relation to patient characteristics, comorbidities, and treatment of HCV with DAAs were estimated by linear mixed models. Costs were reported in Swiss francs (CHF).</p><p><strong>Results: </strong>The final linked file contained 1830 individuals from 11 286 participants of the Swiss HIV Cohort Study and 5406 claims records (33.9%). The mean adjusted annual overall cost in 2012 was CHF 24 713 (SD, 14 107) and increased in 2017 by 1.2% to CHF 24 881 (SD, 14 523). Costs for ART contributed by far most to overall costs but decreased over time. Mean costs for hospitalizations increased with annual variation by 7.2% from CHF 8727 (SD, 10 473) in 2012 to CHF 9406 (SD, 9696) in 2017. Mean increases of costs for DAAs for 171 PWH coinfected with HCV (9.4%) were CHF 52 647 (95% CI, 50 862-54 431; <i>P</i> < .01).</p><p><strong>Conclusions: </strong>Increases in mean total costs for PWH in Switzerland from 2012 to 2017 were small. The contribution of DAAs for the treatment of chronic HCV to overall costs was marginal.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf410"},"PeriodicalIF":3.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ariana M Virgillio, Emily A Felton, Jessica K Jackson, Sarah J Kennedy, Deanna N Becker, Amorce Lima, Kimberly Atrubin, Eleonora Cella, Taj Azarian, Suzane Silbert, Lindsey N Shaw, Kami Kim
{"title":"Genomic and Phenotypic Characterization of Mupirocin-resistant <i>Staphylococcus aureus</i> Clinical Isolates.","authors":"Ariana M Virgillio, Emily A Felton, Jessica K Jackson, Sarah J Kennedy, Deanna N Becker, Amorce Lima, Kimberly Atrubin, Eleonora Cella, Taj Azarian, Suzane Silbert, Lindsey N Shaw, Kami Kim","doi":"10.1093/ofid/ofaf374","DOIUrl":"10.1093/ofid/ofaf374","url":null,"abstract":"<p><strong>Background: </strong>Colonization with <i>Staphylococcus aureus</i> is a risk factor for subsequent infection. Decolonization with the topical antibiotic mupirocin is effective and reduces the risk of subsequent <i>S. aureus</i> infection for both methicillin-sensitive and methicillin-resistant (MRSA) strains but may select for mupirocin-resistant isolates.</p><p><strong>Methods: </strong>We characterized oxacillin and mupirocin susceptibility amongst 384 <i>S. aureus</i> strains isolated from clinical samples isolated in 2017-2023 in Tampa, Florida, spanning strains collected before and after the onset of the coronavirus disease 2019 (COVID-19) pandemic. Whole genome sequencing of bacterial isolates was conducted in parallel and correlated with drug susceptibility profiles.</p><p><strong>Results: </strong>Mupirocin resistance (MupR) was nearly exclusively present in MRSA strains (103/106, 97.1% of MupR; 103/299, 34.4% of MRSA). Although our hospital protocol for decolonization shifted to povidone iodine in the post-COVID period, the overall prevalence of MupR did not change in pre-COVID and post-COVID samples (28.9% vs 26%). Genotype correlated with antibiotic susceptibility with low-level MupR, linked to mutations in <i>ileS</i> and high-level MupR, linked to the presence of <i>mupA</i>. Genome analysis revealed that most MupR strains fell into 3 sequence types (ST) falling into 2 major clonal complexes (CC): CC8 ST8 (including community-associated MRSA strains USA300 and USA500), CC5 ST5 (associated with healthcare-associated MRSA such as USA100), and CC5 ST3390. ST3390 isolates had the highest prevalence of MupR (30/36 83%; high-level MupR 20/36 55.6%; low-level MupR 10/36 27.8%).</p><p><strong>Conclusions: </strong>Mupirocin resistance was prevalent in our hospital MRSA strains. We also found evidence for emergence and persistence of ST3390 MRSA-MupR strains in Florida.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf374"},"PeriodicalIF":3.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12282342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hao Min Cheo, Darren Yan Kit Ho, Lin Pin Koh, Matthew Chung Yi Koh, Jinghao Nicholas Ngiam, David Chien Boon Lye
{"title":"Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis.","authors":"Hao Min Cheo, Darren Yan Kit Ho, Lin Pin Koh, Matthew Chung Yi Koh, Jinghao Nicholas Ngiam, David Chien Boon Lye","doi":"10.1093/ofid/ofaf413","DOIUrl":"10.1093/ofid/ofaf413","url":null,"abstract":"<p><strong>Background: </strong>The optimal antibiotic choice for AmpC-producing Enterobacterales bloodstream infections (BSIs) and complicated urinary tract infections (cUTIs) remains to be clearly defined. Guidance from the Infectious Diseases Society of America recommends cefepime as first-line therapy, based on observational studies. We conducted a systematic review and meta-analysis to compare the clinical outcomes of cefepime versus carbapenems in patients with infections caused by AmpC-producing Enterobacterales.</p><p><strong>Methods: </strong>A systematic search was conducted across Medline, Embase, Cochrane, and Scopus databases to identify studies comparing cefepime and carbapenems for the treatment of BSIs and cUTIs due to AmpC-producing Enterobacterales. Eligible studies reported all-cause mortality as the primary outcome. Secondary outcomes included clinical and microbiological cure, relapse, and adverse events. A random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Seven studies on BSI encompassing 1099 patients were included, with 479 receiving cefepime and 620 receiving carbapenem as definitive antibiotics. There were no studies on cUTI. No statistically significant difference in all-cause mortality was observed between cefepime and carbapenem treatment (log OR, 0.15 [95% CI, -.33 to .64]; <i>P</i> = .54), although a nonsignificant trend favored cefepime, particularly in the subgroup of larger observational studies (n ≥ 50 patients) and more recent studies (published after 2019). Relapse rates were also comparable between the 2 groups (log OR, 0.39 [95% CI, -.25 to 1.03]; <i>P</i> = .23).</p><p><strong>Conclusions: </strong>In line with published guidance, treatment outcomes with cefepime did not differ significantly from carbapenems for AmpC-producing BSIs. However, randomized controlled trials are needed to validate these findings. <b>Clinical Trials Registration.</b> PROSPERO: CRD42025634449.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf413"},"PeriodicalIF":3.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implant Infectious Diseases: An Introduction to Biomaterials for ID Physicians.","authors":"Lauren E Kemp, Alexander M Tatara","doi":"10.1093/ofid/ofaf411","DOIUrl":"https://doi.org/10.1093/ofid/ofaf411","url":null,"abstract":"<p><p>Implanted biomedical devices are becoming ubiquitous in the practice of medicine but are at risk for biofilm-related infection. The biomaterial composition of these devices can significantly affect their risk for infection. Biomaterials design is complex with compositional choices leading to different properties, including mechanical strength, biodegradation rate, and ability to locally release therapeutics. In this review, we introduce the field of \"Implant Infectious Diseases,\" review practical biomaterial fundamentals for the infectious disease clinician, and apply these principles to case vignettes. This review serves as a primer for a broad infectious disease audience to better understand the role of biomaterials in medical devices and as therapeutics.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 8","pages":"ofaf411"},"PeriodicalIF":3.8,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brandi M Mize, Emily Laskey, Gregory L Damhorst, Colleen S Kraft, Guillermo A Escobar
{"title":"Two Cases of Mycotic Aneurysms Caused by <i>Brucella suis</i> Infection of Aortic Graft Material.","authors":"Brandi M Mize, Emily Laskey, Gregory L Damhorst, Colleen S Kraft, Guillermo A Escobar","doi":"10.1093/ofid/ofaf404","DOIUrl":"10.1093/ofid/ofaf404","url":null,"abstract":"<p><p><i>Brucella suis</i>, a zoonotic pathogen, can affect multiple human organ systems causing various clinical manifestations. While aortoiliac involvement is rare worldwide, we report 2 cases of aortic brucellosis following abdominal aortic aneurysm repairs within a 9-year period at a single US institution in Georgia. One case was an infected aortic endograft, which may be the first reported. <i>B suis</i> aortoiliac infections are rare even in endemic areas, thus highlighting how uncommon these cases are in Georgia. Acknowledging the dismal prognosis with symptomatic aortic graft infections, we wish to share our experience in successfully treating them, including an infected aortic endograft. We recommend obtaining a robust history when evaluating individuals with suspected mycotic aneurysms who frequently handle animals. Education on protective equipment and proper handling of animals is imperative to reduce the risk of aortic graft brucellosis infections. Our institutional experience suggests that graft explantation and doxycycline-rifampin are acceptable treatment options.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf404"},"PeriodicalIF":3.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kaitlin Benedict, Ian Hennessee, Gail Sondermeyer Cooksey, Fariba M Donovan, George R Thompson, Thomas Williamson, Mitsuru Toda
{"title":"Comparison of Patients With Coccidioidomycosis in Arizona Versus California: A Commercial Health Insurance Claims Analysis.","authors":"Kaitlin Benedict, Ian Hennessee, Gail Sondermeyer Cooksey, Fariba M Donovan, George R Thompson, Thomas Williamson, Mitsuru Toda","doi":"10.1093/ofid/ofaf405","DOIUrl":"10.1093/ofid/ofaf405","url":null,"abstract":"<p><p>Commercially insured patients with coccidioidomycosis in Arizona (n = 1640) were more likely to have symptoms indicating acute pulmonary disease (eg, cough, dyspnea, chest pain) compared with patients in California (n = 701), who were more likely to have disseminated coccidioidomycosis, possibly reflecting differences in exposure, healthcare seeking, or clinical management.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf405"},"PeriodicalIF":3.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Angela K Ulrich, Nicolina M Moua, Alison Mack, Natsuko Imai-Eaton, J Erin Staples, Angela J Mehr, Julia T Ostrowsky, Tabitha Leighton, Ana Cehovin, Petra C Fay, Josephine P Golding, Emma Maynard, Luke Alphey, Diana P Rojas Alvarez, Lark L Coffey, Nuno R Faria, Rafael Maciel-de-Freitas, Kevin Maringer, Kris A Murray, Henrik Salje, Rosemary Sang, Pedro F C Vasconcelos, Yee-Sin Leo, Steven P Sinkins, Jocelyne Neto de Vasconcelos, Samuel K Dadzie, Eva Harris, Thais H Dos Santos, Raman Velayudhan, Jurai Wongsawat, Michael T Osterholm, Eve M Lackritz
{"title":"Meeting Report on an Integrated Research Agenda for Mosquito-Borne Arboviruses.","authors":"Angela K Ulrich, Nicolina M Moua, Alison Mack, Natsuko Imai-Eaton, J Erin Staples, Angela J Mehr, Julia T Ostrowsky, Tabitha Leighton, Ana Cehovin, Petra C Fay, Josephine P Golding, Emma Maynard, Luke Alphey, Diana P Rojas Alvarez, Lark L Coffey, Nuno R Faria, Rafael Maciel-de-Freitas, Kevin Maringer, Kris A Murray, Henrik Salje, Rosemary Sang, Pedro F C Vasconcelos, Yee-Sin Leo, Steven P Sinkins, Jocelyne Neto de Vasconcelos, Samuel K Dadzie, Eva Harris, Thais H Dos Santos, Raman Velayudhan, Jurai Wongsawat, Michael T Osterholm, Eve M Lackritz","doi":"10.1093/ofid/ofaf395","DOIUrl":"10.1093/ofid/ofaf395","url":null,"abstract":"<p><p>The emergence and re-emergence of mosquito-borne arbovirus (MBV) diseases pose a rapidly expanding global health threat fueled by the convergence of multiple ecologic, economic, and social factors, including climate change, land use, poverty, deficiencies of water storage and sanitation, and limitations of vector control programs. On December 6, 2023, the Wellcome Trust and the University of Minnesota's Center for Infectious Disease Research and Policy held a meeting titled \"An integrated approach to mosquito-borne arboviruses: a priority research agenda.\" The meeting comprised presentations, panels, and facilitated discussions aimed at describing the state of the field, highlighting recent accomplishments, identifying novel strategies, and defining priority research goals and approaches for addressing MBV disease preparedness and response. This report summarizes meeting discussions in 3 key areas: the changing epidemiology of MBV disease, current and potential transmission- and disease-monitoring strategies, and evolutionary impacts on disease burden and transmission. It concludes with a list of priority strategies for research and investment in MBV disease prevention, preparedness, and control. To prepare for future epidemics of MBV diseases, research and policy will benefit from a multipathogen approach to MBVs. Building on existing knowledge and systems, these efforts must address social and ecological factors and connect with other global health agendas.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"12 7","pages":"ofaf395"},"PeriodicalIF":3.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}